Sale!

Acute Leukemia Mini Panel AMLETO INV16 PMLRARA BCRABL TELAML1 MLL E2A Test

2,340 د.إ

-10%

The Acute Leukemia Mini Panel, also known as AMLETO, is a comprehensive diagnostic test specifically designed to identify key genetic mutations and translocations associated with acute leukemia. This panel focuses on several critical markers, including INV16, PML-RARA, BCR-ABL, TEL-AML1, MLL, and E2A, which are pivotal in diagnosing, prognosticating, and guiding the treatment strategies for patients with acute leukemia.

Performed at DNA Labs UAE, a reputable facility known for its advanced genetic testing capabilities, the AMLETO panel employs sophisticated molecular techniques to detect the presence of these genetic abnormalities. By targeting these specific markers, the test provides valuable insights into the subtype of leukemia, helping healthcare professionals tailor treatment plans to the individual patient’s genetic profile.

The cost of the Acute Leukemia Mini Panel AMLETO at DNA Labs UAE is 2340 AED. This investment in precise genetic testing can be crucial for achieving better outcomes in the management of acute leukemia, enabling more personalized and effective treatment approaches.

Home  Sample collection service available

  • 100% accuaret DNA Results
  • Ranked as Most trusted Genetic DNA Lab
Guaranteed Safe Checkout

Acute Leukemia Mini Panel AMLETO INV16 PMLRARA BCRABL TELAML1 MLL E2A Test

Test Details

The Acute Leukemia Mini Panel includes the following genetic abnormalities associated with acute leukemia:

  1. AML/ETO: This fusion gene is formed by the translocation of genetic material between chromosomes 8 and 21. It is commonly found in Acute Myeloid Leukemia (AML) and is associated with a favorable prognosis.
  2. INV[16]: This genetic abnormality involves an inversion of genetic material on chromosome 16. It is associated with a subtype of AML called Acute Myelomonocytic Leukemia with Inversion 16 (AML M4Eo).
  3. PML/RARA: This fusion gene is formed by the translocation of genetic material between chromosomes 15 and 17. It is commonly found in Acute Promyelocytic Leukemia (APL) and is associated with a favorable prognosis.
  4. BCR/ABL: This fusion gene is formed by the translocation of genetic material between chromosomes 9 and 22. It is commonly found in Chronic Myeloid Leukemia (CML) and a subset of Acute Lymphoblastic Leukemia (ALL). The presence of this fusion gene is associated with a poor prognosis.
  5. TEL/AML1: This fusion gene is formed by the translocation of genetic material between chromosomes 12 and 21. It is commonly found in childhood Acute Lymphoblastic Leukemia (ALL) and is associated with a favorable prognosis.
  6. MLL: This gene, also known as MLLT1, is frequently involved in translocations with various partner genes. MLL rearrangements are commonly found in both AML and ALL and are associated with a poor prognosis.
  7. E2A: This gene, also known as TCF3, is involved in translocations with various partner genes. E2A rearrangements are commonly found in ALL and are associated with a poor prognosis.

These genetic abnormalities are detected using molecular genetic techniques such as polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH). Identification of these abnormalities helps in the diagnosis, risk stratification, and treatment planning for patients with acute leukemia.

Test Information

  • Test Name: Acute Leukemia Mini Panel AMLETO INV16 PMLRARA BCRABL TELAML1 MLL E2A Test
  • Components: EDTA Vacutainer (2ml)
  • Price: 2340.0 AED
  • Sample Condition: Bone marrow / Peripheral blood (Transport immediately)
  • Report Delivery: 5-6 days
  • Method: Real Time PCR
  • Test type: Genetics
  • Doctor: General Physician
  • Test Department: Pre Test Information

Pre Test Information

The Acute Leukemia Mini Panel (AML/ETO, INV 16, PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) can be done with a doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Name Acute Leukemia Mini Panel AMLETO INV16 PMLRARA BCRABL TELAML1 MLL E2A Test
Components EDTA Vacutainer (2ml)
Price 2340.0 AED
Sample Condition Bone marrow \/ Peripheral blood (Transport immediately)
Report Delivery 5-6 days
Method Real Time PCR
Test type Genetics
Doctor General Physician
Test Department:
Pre Test Information Acute Leukemia Mini Panel (AML/ETO, INV 16], PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

The Acute Leukemia Mini Panel includes the following genetic abnormalities associated with acute leukemia:

1. AML/ETO: This fusion gene is formed by the translocation of genetic material between chromosomes 8 and 21. It is commonly found in Acute Myeloid Leukemia (AML) and is associated with a favorable prognosis.

2. INV[16]: This genetic abnormality involves an inversion of genetic material on chromosome 16. It is associated with a subtype of AML called Acute Myelomonocytic Leukemia with Inversion 16 (AML M4Eo).

3. PML/RARA: This fusion gene is formed by the translocation of genetic material between chromosomes 15 and 17. It is commonly found in Acute Promyelocytic Leukemia (APL) and is associated with a favorable prognosis.

4. BCR/ABL: This fusion gene is formed by the translocation of genetic material between chromosomes 9 and 22. It is commonly found in Chronic Myeloid Leukemia (CML) and a subset of Acute Lymphoblastic Leukemia (ALL). The presence of this fusion gene is associated with a poor prognosis.

5. TEL/AML1: This fusion gene is formed by the translocation of genetic material between chromosomes 12 and 21. It is commonly found in childhood Acute Lymphoblastic Leukemia (ALL) and is associated with a favorable prognosis.

6. MLL: This gene, also known as MLLT1, is frequently involved in translocations with various partner genes. MLL rearrangements are commonly found in both AML and ALL and are associated with a poor prognosis.

7. E2A: This gene, also known as TCF3, is involved in translocations with various partner genes. E2A rearrangements are commonly found in ALL and are associated with a poor prognosis.

These genetic abnormalities are detected using molecular genetic techniques such as polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH). Identification of these abnormalities helps in the diagnosis, risk stratification, and treatment planning for patients with acute leukemia.